GENEVA GRADUATE INSTITUTE | GLOBAL HEALTH CENTRE

References

Arksey, H., & O'Malley, L. (2005). Scoping studies: Towards a methodological framework. International Journal of Social Research Methodology, 8(1), 19–32. https://doi.org/10.1080/1364557032000119616

Arno, P. S., Bonuck, K., & Davis, M. (1995). Rare diseases, drug development, and AIDS: The impact of the Orphan Drug Act. The Milbank Quarterly, 73(2), 231–252.

Asbury, C. H. (1981). Medical drugs of limited commercial interest: Profit alone is a bitter pill. International Journal of Health Services. https://doi.org/10.2190/neld-fbm5-ffn3-0flc

Asbury, C. H. (1991). The Orphan Drug Act. The first 7 years. JAMA, 265(7), 893–897.

Asbury, C. H. (1992). Evolution and current status of the Orphan Drug Act. International Journal of Technology Assessment in Health Care, 8(4), 573–582.

Aymé, S., Kole, A., & Groft, S. (2008). Empowerment of patients: Lessons from the rare diseases community. The Lancet, 371(9629), 2048–2051. https://doi.org/10.1016/S0140-6736(08)60875-2

Braun, M. M., Braun, M. M., Farag-El-Massah, S., Farag-El-Massah, S., Xu, K., & Coté, T. R. (2010). Emergence of orphan drugs in the United States: A quantitative assessment of the first 25 years. Nature Reviews Drug Discovery https://doi.org/10.1038/nrd3160

Chan, A. Y. L., Chan, A. Y. L., Li, S. X., Chan, A. Y. L., Chan, V. K. Y., Chan, V. K. Y., Chan, A., Chan, V. K. Y., Olsson, S., Chan, V. K. Y., Olsson, S., Fan, M., Olsson, S., Fan, M., Fan, M., Zhang, S., Gong, M., Fan, M., Jit, M., … Li, X. (2020). Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis. Value in Health. https://doi.org/10.1016/j.jval.2020.06.020

Cheng, A., & Xie, Z. (2017). Challenges in orphan drug development and regulatory policy in China. Orphanet Journal of Rare Diseases, 12(1), 13. https://doi.org/10.1186/s13023-017-0568-6

Cheung, R. Y., Cohen, J. C., & Illingworth, P. (2004). Orphan drug policies: Implications for the United States, Canada, and developing countries. Health Law Journal, 12, 183–200.

Clissold, D. B. (1995). Prescription for the Orphan Drug Act: The Impact of the FDA's 1992 Regulations and the Latest Congressional Proposals for Reform. Food and Drug Law Journal, 50(1), 125–147.

Cohen, D., & Raftery, J. (2014). Paying twice: Questions over high cost of cystic fibrosis drug developed with charitable funding. BMJ (Online), 348(February), 10–13. https://doi.org/10.1136/bmj.g1445

Committee for Orphan Medicinal Products and the European Medicines, Westermark, K., Holm, B. B., Söderholm, M., Llinares-Garcia, J., Rivière, F., Aarum, S., Butlen-Ducuing, F., Tsigkos, S., Wilk-Kachlicka, A., N'Diamoi, C., Borvendég, J., Lyons, D., Sepodes, B., Bloechl-Daum, B., Lhoir, A., Todorova, M., Kkolos, I., Kubáčková, K., … Belorgey, C. (2011). European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nature Reviews. Drug Discovery, 10(5), 341–349. https://doi.org/10.1038/nrd3445

Côté, A., & Keating, B. (2012). What Is Wrong with Orphan Drug Policies. Value in Health. https://doi.org/10.1016/j.jval.2012.09.004

Daniel, M., Pawlik, T. M., Fader, A. N., Fader, A. N., Fader, A. N. N., Esnaola, N. F., & Makary, M. A. (2016). The Orphan Drug Act: Restoring the Mission to Rare Diseases. American Journal of Clinical Oncology. https://doi.org/10.1097/coc.0000000000000251

Davidson, S. (1996). Orphan drugs: European biotechnology waits for EC act. Nature Biotechnology, 14(4), Article 4. https://doi.org/10.1038/nbt0496-419b

Davies, E. H., Fulton, E., Brook, D., & Hughes, D. A. (2017). Affordable orphan drugs: A role for not-for-profit organizations. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.13240

Dear, J. W., Lilitkarntakul, P., & Webb, D. J. (2006). Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. British Journal of Clinical Pharmacology, 62(3), 264–271. https://doi.org/10.1111/j.1365-2125.2006.02654.x

Dunkle, M., Pines, W., & Saltonstall, P. L. (2010). Advocacy Groups and Their Role in Rare Diseases Research. In M. Posada de la Paz & S. C. Groft (Eds.), Rare Diseases Epidemiology (pp. 515–525). https://doi.org/10.1007/978-90-481-9485-8_28

Ferreira, C. R. (2019). The burden of rare diseases. American Journal of Medical Genetics Part A, 179(6), 885–892. https://doi.org/10.1002/ajmg.a.61124

Garber, A. M. (1994). Benefits versus profits: Has the orphan drug act gone too far? PharmacoEconomics, 5(2), 88–92. https://doi.org/10.2165/00019053-199405020-00002

Giannuzzi, V., Conte, R., Landi, A., Ottomano, S. A., Bonifazi, D., Baiardi, P., Bonifazi, F., & Ceci, A. (2017). Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: An increased common effort is to be foreseen. Orphanet Journal of Rare Diseases, 12(1), 64. https://doi.org/10.1186/s13023-017-0617-1

Haffner, M. E. (1991). Orphan Products: Origins, Progress, and Prospects. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev.pa.31.040191.003131

Haffner, M. E. (1999). Orphan Drugs: The United States Experience. Drug Information Journal, 33(2), 565–568. https://doi.org/10.1177/009286159903300226

Haffner, M. E. (2003). The Current Environment in Orphan Drug Development. Drug Information Journal. https://doi.org/10.1177/009286150303700404

Haffner, M. E. (2006). Adopting orphan drugs–two dozen years of treating rare diseases. The New England Journal of Medicine. https://doi.org/10.1056/nejmp058317

Haffner, M. E., & Maher, P. D. (2006). The impact of the Orphan Drug Act on drug discovery. Expert Opinion on Drug Discovery, 1(6), 521–524.

Haffner, M. E., Torrent-Farnell, J., & Maher, P. D. (2008). Does orphan drug legislation really answer the needs of patients. The Lancet. https://doi.org/10.1016/s0140-6736(08)60873-9

Haffner, M. E., Whitley, J., & Moses, M. (2002). Two decades of orphan product development. Nature Reviews. Drug Discovery, 1(10), 821–825.

Heemstra, H. E., Vrueh, R. L. A. de, Weely, S. van, Büller, H. A., Büller, H. A., & Leufkens, H. G. M. (2008). Predictors of orphan drug approval in the European Union. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-007-0454-6

Hendrickx, K., Hendrickx, K., & Dooms, M. (2021). Orphan Drugs, Compounded Medication and Pharmaceutical Commons. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.738458

Herder, M. (2013). When Everyone is an Orphan: Against Adopting a US-Styled Orphan Drug Policy in Canada. Accountability in Research. https://doi.org/10.1080/08989621.2013.793120

Horgan, D., Moss, B., Boccia, S., Genuardi, M., Gajewski, M., Capurso, G., Fenaux, P., Gulbis, B., Pellegrini, M., Mañú Pereira, M. del M., Gutiérrez Valle, V., Gutiérrez Ibarluzea, I., Kent, A., Cattaneo, I., Jagielska, B., Belina, I., Tumiene, B., Ward, A., & Papaluca, M. (2020). Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases – Is It Time to Update the EU's Orphan Regulation? And if so, What Should be Changed? Biomedicine Hub, 5(2), 1–11. https://doi.org/10.1159/000509272

Huyard, C. (2009). How did uncommon disorders become 'rare diseases'? History of a boundary object. Sociology of Health and Illness, 31(4), 463–477. https://doi.org/10.1111/j.1467-9566.2008.01143.x

Joppi, R., Bertele, V., & Garattini, S. (2006). Orphan drug development is progressing too slowly. British Journal of Clinical Pharmacology, 61(3), 355–360.

Joppi, R., Bertele, V., & Garattini, S. (2009). Orphan drug development is not taking off. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2009.03369.x

Kanavos, P., & Nicod, E. (2012). What is wrong with orphan drug policies? Suggestions for ways forward. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 15(8), 1182–1184.

Kesselheim, A. S. (2010). Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation. The New England Journal of Medicine, 363(19), 1862–1855. https://doi.org/10.1056/NEJMhle1002961

Kesselheim, A. S. (2011). An empirical review of major legislation affecting drug development: Past experiences, effects, and unintended consequences. Milbank Quarterly. https://doi.org/10.1111/j.1468-0009.2011.00636.x

Kesselheim, A. S., Myers, J. A., & Avorn, J. (2011). Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer. JAMA. https://doi.org/10.1001/jama.2011.769

Kesselheim, A. S., Myers, J. A., Solomon, D. H., Winkelmayer, W. C., Winkelmayer, W. C., Levin, R., & Avorn, J. (2012). The prevalence and cost of unapproved uses of top-selling orphan drugs. PLOS ONE. https://doi.org/10.1371/journal.pone.0031894

Kesselheim, A. S., Tan, Y. T., & Avorn, J. (2015). The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs. Health Affairs. https://doi.org/10.1377/hlthaff.2014.1038

Koay, P. P., & Sharp, R. R. (2013). The Role of Patient Advocacy Organizations in Shaping Genomic Science. Annual Review of Genomics and Human Genetics, 14(1), 579–595. https://doi.org/10.1146/annurev-genom-091212-153525

Liu, B., He, L., He, G., & He, Y. (2010). A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: Towards a made-in-China orphan drug policy. Journal of Public Health Policy, 31(4), 407–420; discussion 420-421. https://doi.org/10.1057/jphp.2010.30

Loughnot, D. (2005). Potential Interactions of the Orphan Drug Act and Pharmacogenomics: A Flood of Orphan Drugs and Abuses? American Journal of Law & Medicine, 31(2–3), 365–380. https://doi.org/10.1177/009885880503100210

Luzzatto, L., Hollak, C. E. M., Cox, T. M., Schieppati, A., Licht, C., Kääriäinen, H., Merlini, G., Schaefer, F., Simoens, S., Pani, L., Garattini, S., & Remuzzi, G. (2015). Rare diseases and effective treatments: Are we delivering? The Lancet, 385(9970), 750–752. https://doi.org/10.1016/S0140-6736(15)60297-5

McCabe, C., Stafinski, T., & Menon, D. (2010). Is it time to revisit orphan drug policies. BMJ. https://doi.org/10.1136/bmj.c4777

Meekings, K. N., Williams, C. S. M., & Arrowsmith, J. E. (2012). Orphan drug development: An economically viable strategy for biopharma R&D. Drug Discovery Today, 17(13), 660–664.

Menon, D., Stafinski, T., Dunn, A., & Wong-Rieger, D. (2015). Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle. The Patient - Patient-Centered Outcomes Research, 8(1), 103–117. https://doi.org/10.1007/s40271-014-0108-6

Mestre-Ferrandiz, J., Palaska, C., Kelly, T., Hutchings, A., & Parnaby, A. (2019). An analysis of orphan medicine expenditure in Europe: Is it sustainable? Orphanet Journal of Rare Diseases, 14(1), 287. https://doi.org/10.1186/s13023-019-1246-7

Mikami, K. (2017). Orphans in the Market: The History of Orphan Drug Policy. Social History of Medicine. https://doi.org/10.1093/shm/hkx098

Mikami, K., & Sturdy, S. (2017). Patient organization involvement and the challenge of securing access to treatments for rare diseases: Report of a policy engagement workshop. Research Involvement and Engagement, 3(1), 14. https://doi.org/10.1186/s40900-017-0065-z

Miller, K. L. (2017). Do investors value the FDA orphan drug designation? Orphanet Journal of Rare Diseases, 12(1), 114. https://doi.org/10.1186/s13023-017-0665-6

Miller, K. L., Kraft, S., Ipe, A., & Fermaglich, L. (2022). Drugs and biologics receiving FDA orphan drug designation: An analysis of the most frequently designated products and their repositioning strategies. Expert Opinion on Orphan Drugs, 9(11–12), 265–272. https://doi.org/10.1080/21678707.2021.2047021

Murakami, M., & Narukawa, M. (2016). Matched analysis on orphan drug designations and approvals: Cross regional analysis in the United States, the European Union, and Japan. Drug Discovery Today, 21(4), 544–549.

Novas, C. (2009). Orphan Drugs, Patient Activism and Contemporary Healthcare. Quaderni. https://doi.org/10.4000/quaderni.262

Padula, W. V., Parasrampuria, S., Socal, M. P., Conti, R. M., & Anderson, G. F. (2020). Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US. PharmacoEconomics. https://doi.org/10.1007/s40273-020-00934-2

Penington, R. C., Penington, R., & Stubbings, J. A. (2016). Evaluation of Specialty Drug Price Trends Using Data from Retrospective Pharmacy Sales Transactions. Journal of Managed Care Pharmacy. https://doi.org/10.18553/jmcp.2016.22.9.1010

Provost, G. P. (1968). "Homeless" or "Orphan" Drugs. American Journal of Hospital Pharmacy, 25(11), 609. https://doi.org/10.1093/ajhp/25.11.609

Rollet, P., Lemoine, A., & Dunoyer, M. (2013). Sustainable rare diseases business and drug access: No time for misconceptions. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-8-109

Sarpatwari, A., Beall, R. F., Abdurrob, A., He, M., He, M., & Kesselheim, A. S. (2018). Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period. Health Affairs. https://doi.org/10.1377/hlthaff.2017.1179

Sarpatwari, A., & Kesselheim, A. S. (2019). Reforming the Orphan Drug Act for the 21st Century. New England Journal of Medicine, 381(2), 104–106. https://doi.org/DOI: 10.1056/NEJMp1902943

Seoane-Vazquez, E., Rodriguez-Monguio, R., Szeinbach, S. L., & Visaria, J. (2008). Incentives for orphan drug research and development in the United States. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-3-33

Shiragami, M., & Nakai, K. (2000a). Development of Orphan Drugs in Japan: Characteristics of Orphan Drugs Developed in Japan. Drug Information Journal, 34(3), 839–846. https://doi.org/10.1177/009286150003400320

Shiragami, M., & Nakai, K. (2000b). Development of Orphan Drugs in Japan: Effects of a Support System for Development of Orphan Drugs in Japan. Drug Information Journal, 34(3), 829–837. https://doi.org/10.1177/009286150003400319

Shulman, S. R., & Manocchia, M. (1997). The US orphan drug programme 1983-1995. PharmacoEconomics, 12(3), 312–326.

Song, P., Tang, W., & Kokudo, N. (2013). Rare diseases and orphan drugs in Japan: Developing multiple strategies of regulation and research. Expert Opinion on Orphan Drugs, 1(9), 681–683. https://doi.org/10.1517/21678707.2013.832201

Sunyoto, T., Potet, J., & Boelaert, M. (2018). Why miltefosine—A life-saving drug for leishmaniasis—Is unavailable to people who need it the most. BMJ Global Health. https://doi.org/10.1136/bmjgh-2018-000709

Tambuyzer, E. (2010). Rare diseases, orphan drugs and their regulation: Questions and misconceptions. Nature Reviews. Drug Discovery, 9(12), 921–929. https://doi.org/10.1038/nrd3275

Thamer, M., Brennan, N., & Semansky, R. (1998). A cross-national comparison of orphan drug policies: Implications for the U.S. Orphan Drug Act. Journal of Health Politics, Policy and Law, 23(2), 265–290. https://doi.org/10.1215/03616878-23-2-265

Towse, A., & Kettler, H. (2005). A review of IP and non-IP incentives for R&D for diseases of poverty. What type of innovation is required and how can we incentivise the private sector to deliver it? Innovation and Public Health

.

Trouiller, P., Olliaro, P., Olliaro, P., Torreele, E., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002). Drug development for neglected diseases: A deficient market and a public-health policy failure. The Lancet. https://doi.org/10.1016/s0140-6736(02)09096-7

Uchida, K. (1996). Orphan Drugs in Japan. Drug Information Journal, 30(1), 171–175. https://doi.org/10.1177/009286159603000119

Valverde, A. M., Reed, S. D., & Schulman, K. A. (2012). Proposed 'Grant-And-Access' Program With Price Caps Could Stimulate Development Of Drugs For Very Rare Diseases. Health Affairs. https://doi.org/10.1377/hlthaff.2012.0235

Van Woert, M. H. (1978). Profitable and Nonprofitable Drugs. New England Journal of Medicine, 298(16), 903–906. https://doi.org/10.1056/NEJM197804202981608

Wellman-Labadie, O., & Zhou, Y. (2010). The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? Health Policy. https://doi.org/10.1016/j.healthpol.2009.12.001

Wolinsky, H. (2017). Charities and the lure of capitalism: Philanthropies dedicated to finding cures for rare diseases explore new models for funding and cooperation to accelerate research and drug development. EMBO Reports. https://doi.org/10.15252/embr.201744065

Yin, W. (2008). Market incentives and pharmaceutical innovation. Journal of Health Economics. https://doi.org/10.1016/j.jhealeco.2008.01.002

Yin, W. (2009). R&D policy, agency costs and innovation in personalized medicine. Journal of Health Economics. https://doi.org/10.1016/j.jhealeco.2009.06.011

Zhang, L., & Wang, J. (2021). Incentives to promote the US pharmaceutical innovation: Empirical research based on the case of Epogen. Drug Development and Industrial Pharmacy. https://doi.org/10.1080/03639045.2021.1935997